Northwest Biotherapeutics Stock Performance
| NWBO Stock | USD 0.46 0.01 2.13% |
The company secures a Beta (Market Risk) of 0.54, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Northwest Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Northwest Biotherapeutics is expected to be smaller as well. Northwest Biotherapeutics has an expected return of -0.32%. Please make sure to verify Northwest Biotherapeutics maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Northwest Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Northwest Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in May 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 10 M | |
| Total Cashflows From Investing Activities | -6 M |
Northwest |
Northwest Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 59.00 in Northwest Biotherapeutics on January 25, 2024 and sell it today you would lose (13.00) from holding Northwest Biotherapeutics or give up 22.03% of portfolio value over 90 days. Northwest Biotherapeutics is currently does not generate positive expected returns and assumes 3.9419% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of otc stocks are less volatile than Northwest, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Northwest Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Northwest Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Northwest Biotherapeutics, and traders can use it to determine the average amount a Northwest Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0807
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NWBO |
Estimated Market Risk
| 3.94 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Northwest Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Northwest Biotherapeutics by adding Northwest Biotherapeutics to a well-diversified portfolio.
Northwest Biotherapeutics Fundamentals Growth
Northwest OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Northwest Biotherapeutics, and Northwest Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Northwest OTC Stock performance.
| Return On Asset | -1.26 | ||||
| Profit Margin | 52.10 % | ||||
| Operating Margin | (54.95) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 1.05 B | ||||
| Price To Earning | 58.17 X | ||||
| Price To Sales | 858.96 X | ||||
| Revenue | 1 M | ||||
| EBITDA | 184.72 M | ||||
| Cash And Equivalents | 9.43 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 25.16 M | ||||
| Debt To Equity | (16.14) % | ||||
| Book Value Per Share | (0.10) X | ||||
| Cash Flow From Operations | (38.3 M) | ||||
| Earnings Per Share | (0.06) X | ||||
| Total Asset | 40.16 M | ||||
| Retained Earnings | (862.01 M) | ||||
| Current Asset | 24.1 M | ||||
| Current Liabilities | 64.93 M | ||||
About Northwest Biotherapeutics Performance
To evaluate Northwest Biotherapeutics OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Northwest Biotherapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Northwest OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Northwest Biotherapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Northwest's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.Things to note about Northwest Biotherapeutics performance evaluation
Checking the ongoing alerts about Northwest Biotherapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Northwest Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Northwest Biotherapeutics generated a negative expected return over the last 90 days | |
| Northwest Biotherapeutics has some characteristics of a very speculative penny stock | |
| Northwest Biotherapeutics has high historical volatility and very poor performance | |
| Northwest Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company currently holds 25.16 M in liabilities. Northwest Biotherapeutics has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Northwest Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Northwest Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Northwest Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Northwest to invest in growth at high rates of return. When we think about Northwest Biotherapeutics' use of debt, we should always consider it together with cash and equity. | |
| Northwest Biotherapeutics currently holds about 9.43 M in cash with (38.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Northwest Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Northwest Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Northwest Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Northwest Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Northwest Biotherapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Northwest Biotherapeutics' otc stock. These opinions can provide insight into Northwest Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Northwest Biotherapeutics. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Northwest Biotherapeutics information on this page should be used as a complementary analysis to other Northwest Biotherapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Northwest OTC Stock analysis
When running Northwest Biotherapeutics' price analysis, check to measure Northwest Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Northwest Biotherapeutics is operating at the current time. Most of Northwest Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Northwest Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Northwest Biotherapeutics' price. Additionally, you may evaluate how the addition of Northwest Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |